top of page

BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region

Nov 4, 2024

Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as atrogi, empros pharma, and xspray.

Brought to you by

Recent Posts

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Atlas Venture's Bruce Booth shares his take on the current state of biotech and what it takes to get through difficult times for the industry as an investor and for companies

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Cigall Kadoch discusses her pioneering work in chromatin regulation that has led to Foghorn Therapeutics

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

State of Possible: Massachusetts Governor Maura Healey discusses keeping the state on top in life sciences, global competition, and more

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page